Clinical Study
Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease
Table 3
The effect of Q192R and L55M polymorphisms on serum PON1 activity.
| | CAD group | Controls | | PON1 activity (U/L) | | | (%) | (%) | CAD group | Controls |
| Number of subjects (%) | 53 (100) | 53 (100) | 1.0 | 126.58 ± 85.95 | 125.94 ± 79.56 | 0.91 |
| Q192R polymorphism | Genotype | | | | | | | QQ | 32 (60.4) | 31 (58.5) | 0.84 | 66.04 ± 9.64 | 72.28 ± 14.19 | 0.14 | QR | 17 (32.1) | 18 (34) | 0.83 | 196.54 ± 48.24 | 182.76 ± 40.5 | 0.43 | RR | 4 (7.5) | 4 (7.5) | 1.0 | 302.75 ± 91.65 | 313.75 ± 72.28 | 0.85 | 192R allele carriers | 21 (39.6) | 22 (41.5) | 0.84 | 215.05 ± 70.35 | 207.71 ± 67.23 | 0.65 |
| L55M polymorphism | Genotype | | | | | | | LL | 14 (24.6) | 18 (34) | 0.39 | 126.13 ± 77.26 | 136.06 ± 83.35 | 0.44 | LM | 31 (58.5) | 18 (34) | 0.01 | 113.85 ± 68.6 | 112.8 ± 69.43 | 0.54 | MM | 8 (15.1) | 17 (32) | 0.039 | 163.90 ± 134.64 | 122.82 ± 95.62 | 0.74 |
|
|
Data is presented as arithmetic means ± SD; Chi2 test; Mann-Whitney test.
|